Похоже, при загрузке страницы произошла ошибка.
Наша команда получила уведомление. Если проблема сохранится, свяжитесь с нами через виджет поддерж. по email.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | Yes |
| Is net profit margin increasing? | Yes | No |
| Is asset turnover increasing? | No | Yes |
| Is equity multiplier increasing? | No | Yes |
| Competitors Used |
|---|
| Beijing Sun-Novo Pharmaceutical Research Co., Ltd. |
| R&G PharmaStudies Co., Ltd. |
| Zhejiang Tailin BioEngineering Co.,Ltd |
| SMO ClinPlus CO.,LTD. |
| Maccura Biotechnology Co.Ltd |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| 688,621 | 301,333 | 300,813 | 301,257 | 300,463 | 300,404 | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 17% | 8% | 1% | 10% | 5% | 5% | ||
| Fiscal Year - 1 | 19% | 10% | 14% | 12% | 13% | 3% | ||
| Fiscal Year - 2 | 19% | 11% | 13% | 29% | 24% | 6% | ||
| Fiscal Year - 3 | 22% | 27% | 14% | 24% | 23% | 4% | ||
| Fiscal Year - 4 | 47% | 30% | 16% | 54% | 18% | 2% | ||
| Fiscal Year - 5 | 49% | 35% | 28% | 54% | 17% | 2% | ||
| Average | 29% | 20% | 15% | 31% | 17% | 4% | ||
| Median | 21% | 19% | 14% | 27% | 18% | 4% | ||
| Benchmarks | Ticker | |||||||
| Beijing Sun-Novo Pharmaceutical Research Co., Ltd. | SHSE:688621 | |||||||
| R&G PharmaStudies Co., Ltd. | SZSE:301333 | |||||||
| Zhejiang Tailin BioEngineering Co.,Ltd | SZSE:300813 | |||||||
| SMO ClinPlus CO.,LTD. | SZSE:301257 | |||||||
| Maccura Biotechnology Co.Ltd | SZSE:300463 | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | May-85 | Jan-25 | Aug-23 | Oct-24 | Aug-22 | Jun-22 | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-23 | Dec-23 | Dec-23 | Dec-23 | ||
| LTM Period | Dec-24 | Dec-24 | Sep-24 | Sep-24 | Sep-24 | Sep-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 1,078 | 744 | 309 | 810 | 2,728 | 753 | ||
| Fiscal Year | 1,078 | 744 | 270 | 760 | 2,896 | 556 | ||
| Fiscal Year - 1 | 932 | 721 | 374 | 586 | 3,608 | 424 | ||
| Fiscal Year - 2 | 677 | 638 | 283 | 503 | 3,981 | 324 | ||
| Fiscal Year - 3 | 494 | 608 | 200 | 335 | 3,704 | 260 | ||
| Fiscal Year - 4 | 347 | 484 | 181 | 304 | 3,223 | 224 | ||
| Fiscal Year - 5 | 234 | 425 | 159 | 193 | 2,685 | 172 | ||
| Net Income | ||||||||
| Latest Twelve Months | 177 | 140 | 10 | 106 | 325 | 45 | ||
| Fiscal Year | 177 | 140 | 20 | 135 | 313 | 24 | ||
| Fiscal Year - 1 | 185 | 163 | 80 | 72 | 708 | 28 | ||
| Fiscal Year - 2 | 156 | 113 | 64 | 58 | 957 | 39 | ||
| Fiscal Year - 3 | 106 | 99 | 48 | 35 | 794 | 17 | ||
| Fiscal Year - 4 | 72 | 84 | 34 | 52 | 525 | 7 | ||
| Fiscal Year - 5 | 47 | 83 | 48 | 30 | 445 | 7 | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 1,863 | 2,074 | 973 | 1,303 | 8,233 | 1,364 | ||
| Latest Fiscal Quarter | 1,987 | 2,336 | 962 | 1,381 | 8,206 | 1,483 | ||
| Fiscal Year | 1,987 | 2,336 | 974 | 1,367 | 8,119 | 1,429 | ||
| Fiscal Year - 1 | 1,863 | 2,074 | 923 | 1,161 | 8,168 | 1,265 | ||
| Fiscal Year - 2 | 1,464 | 1,883 | 656 | 404 | 6,567 | 1,138 | ||
| Fiscal Year - 3 | 1,243 | 677 | 540 | 287 | 6,365 | 750 | ||
| Fiscal Year - 4 | 385 | 525 | 267 | 202 | 5,497 | 633 | ||
| Fiscal Year - 5 | 286 | 447 | 255 | 138 | 4,556 | 606 | ||
| Fiscal Year - 6 | 201 | NA | 194 | 89 | 3,583 | 575 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 1,040 | 1,748 | 663 | 1,041 | 6,334 | 888 | ||
| Latest Fiscal Quarter | 1,101 | 1,833 | 655 | 1,141 | 6,535 | 983 | ||
| Fiscal Year | 1,101 | 1,833 | 649 | 1,081 | 6,385 | 956 | ||
| Fiscal Year - 1 | 1,040 | 1,748 | 647 | 952 | 6,293 | 855 | ||
| Fiscal Year - 2 | 897 | 1,588 | 497 | 229 | 4,299 | 814 | ||
| Fiscal Year - 3 | 762 | 423 | 444 | 165 | 3,797 | 444 | ||
| Fiscal Year - 4 | 189 | 323 | 229 | 125 | 3,126 | 423 | ||
| Fiscal Year - 5 | 117 | 238 | 195 | 70 | 2,695 | 413 | ||
| Fiscal Year - 6 | 75 | NA | 146 | 43 | 2,501 | 404 | ||